Body: For too long, the supplement industry has operated like a black box, often combining trendy ingredients with little public data to support their synergistic action. Xelyra Biotech is challenging this status quo with a transparent, data-driven methodology used to develop its Lipo405 protocol: the in silico trial.
In silico—meaning “performed on computer or via computer simulation”—is the same cutting-edge technology used in modern drug discovery. By feeding thousands of peer-reviewed studies and data points into an advanced AI model, Xelyra’s researchers could predict how the 8 modules in lipo405 would interact and what their combined effect on cellular aging would be. This allowed them to design for synergy, targeting specific outcomes like the predicted 18% reduction in a key “zombie cell” biomarker and the 23% increase in NK cell activity.
This data-first approach provides an unprecedented level of confidence and transparency. It means Lipo405’s formula isn’t based on guesswork; it’s based on a scientific hypothesis validated by a powerful predictive model. It proves Xelyra Biotech is operating not just as a wellness company, but as a technology company poised to change the future of health.
